Related Experiment Videos
Pediatric granulomatous arthritis: an international registry
Carlos D Rosé1, Carine H Wouters, Silvia Meiorin
1duPont Children's Hospital, Wilmington, Delaware 19899, USA. crose@nemours.org
Insights
Pediatric granulomatous arthritis, including Blau syndrome and early-onset sarcoidosis, is linked to CARD15 mutations. Mutation analysis may be more efficient than skin biopsy for diagnosis.
Area of Science:
- Genetics
- Rheumatology
- Ophthalmology
Background:
- Blau syndrome and early-onset sarcoidosis share a phenotype of arthritis, dermatitis, and uveitis.
- CARD15 mutations are found in 50-90% of these cases.
- An international registry was created to study pediatric granulomatous arthritis.
Purpose of the Study:
- To define the phenotype spectrum of pediatric granulomatous arthritis.
- To establish CARD15 mutation frequency and variants.
- To compare diagnostic approaches.
Main Methods:
- Established an international registry for pediatric granulomatous arthritis.
- Required histological confirmation of granuloma and arthritis for inclusion.
- Genotyped probands and relatives for CARD15 mutations.
Main Results:
- 61 individuals from 22 pedigrees were entered within one year.
- Classic pediatric granulomatous arthritis pedigrees carried CARD15 mutations; atypical cases did not.
- Cutaneous presentation was most common; 41% experienced severe visual impairment, often bilateral, with glaucoma and cataracts.
Conclusions:
- All affected classic pediatric granulomatous arthritis pedigrees carry CARD15 mutations, with no asymptomatic carriage.
- Mutation analysis may be more efficient than tissue sampling for diagnosis.
- Further defined the phenotype of pediatric granulomatous arthritis.
Objective:
Blau syndrome and its sporadic counterpart, early-onset sarcoidosis, share an identical phenotype featuring the classic triad of arthritis, dermatitis, and uveitis and are associated with mutations of CARD15 in 50-90% of cases. We chose the term "pediatric granulomatous arthritis" to refer to both. An international registry was established in the spring of 2005 to define the phenotype spectrum and establish the mutation frequency and variants.
Methods:
Histologically confirmed granuloma and arthritis were required for inclusion. Probands and relatives were genotyped for CARD15. Deidentified clinical information was collected.
Results:
One year after the inception of the registry, 61 individuals from 22 pedigrees had been entered. Seven pedigrees with 19 individuals (8 affected, 11 unaffected) had clinical disease that was atypical, and none of the individuals in those pedigrees showed mutations. There were 9 classic simplex pediatric granulomatous arthritis pedigrees including 19 individuals (9 affected, 10 unaffected) and 6 classic multiplex pedigrees with 22 individuals (17 affected, 5 unaffected). Cutaneous presentation was the most common. Arthritis was polyarticular in 96% of patients. Isolated eye disease was never the presenting symptom, but significant/severe visual impairment was observed in 41% of patients. Eye disease was bilateral in 21 of 22 patients and was complicated by glaucoma in 6 of 22 patients and by cataracts in 50% of patients. Skin biopsy was the best diagnostic approach (because of accuracy and low invasiveness).
Conclusion:
In this series, the first combining familial and sporadic pedigrees and, to our knowledge, the largest, we further defined the phenotype and showed that all affected classic (and no nonclassic) pedigrees carry a mutation and that there is no asymptomatic carriage. If these data are confirmed, mutation analysis rather than tissue sampling may prove to be the most efficient diagnostic procedure.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Distribution